Sodium Sulfide 1% Gel Safety Supported By New Clinical Data - Schering
This article was originally published in The Tan Sheet
Executive Summary
The safety of sodium sulfide gel for the relief of pain associated with ingrown toenails is exhibited by the results of a clinical study conducted by Schering-Plough, the company tells FDA in an Oct. 13 citizen petition. Previous agency concerns regarding the ingredient's safety should be addressed by the findings, the petition says.
You may also be interested in...
Sodium Sulfide 1% Gel Ingrown Toenail Safety Shown By Schering-Plough
Sodium sulfide 1% gel could be included in the OTC monograph for ingrown toenail relief drugs following a public comment period, FDA tells Schering-Plough HealthCare Products in a May 22 letter.
Sodium Sulfide 1% Gel Ingrown Toenail Safety Shown By Schering-Plough
Sodium sulfide 1% gel could be included in the OTC monograph for ingrown toenail relief drugs following a public comment period, FDA tells Schering-Plough HealthCare Products in a May 22 letter.
Sodium Sulfide 1% Gel Ingrown Toenail Safety Shown By Schering-Plough
Sodium sulfide 1% gel could be included in the OTC monograph for ingrown toenail relief drugs following a public comment period, FDA tells Schering-Plough HealthCare Products in a May 22 letter.